Publications in collaboration with researchers from Hospital Universitario San Cecilio (19)

2024

  1. ERRATUM: Pegvisomant and pasireotide in PRL and GH co-secreting vs GH-secreting Pit-NETs

    Endocrine-related cancer

  2. Effectiveness of combined first-line medical treatment in acromegaly with prolactin cosecretion

    European Journal of Endocrinology, Vol. 190, Núm. 6, pp. 458-466

  3. Glucose metabolism outcomes after pituitary surgery in patients with acromegaly

    Pituitary, Vol. 27, Núm. 5, pp. 497-506

  4. Pegvisomant and pasireotide in PRL and GH co-secreting vs GH-secreting Pit-NETs

    Endocrine-Related Cancer, Vol. 31, Núm. 7

2021

  1. Executive summary: Position document: Evaluation and management of hypoglycemia in the patient with diabetes mellitus 2020. Diabetes Mellitus Working Group of the Spanish Society of Endocrinology and Nutrition

    Endocrinologia, Diabetes y Nutricion, Vol. 68, Núm. 4, pp. 270-276

2014

  1. Fe de errores de Guía práctica de diagnóstico y tratamiento de la acromegalia (Endocrinol Nutr. 2013;60(8):457.e1-457.e15)

    Endocrinologia y Nutricion

2013

  1. Changes in acromegaly treatment over four decades in Spain: Analysis of the Spanish Acromegaly Registry (REA)

    Pituitary, Vol. 16, Núm. 1, pp. 115-121

2012

  1. Fe de errores de "Guías de práctica clínica para la evaluación y tratamiento de la osteoporosis asociada a enfermedades endocrinas y nutricionales"

    Endocrinologia y Nutricion

2008

  1. Serum IGF-I measured by four different immunoassays in patients with adult GH deficiency or acromegaly and in a control population

    Clinical Endocrinology, Vol. 68, Núm. 6, pp. 942-950

2007

  1. Long-term efficacy and tolerability of flutamide combined with oral contraception in moderate to severe hirsutism: A 12-month, double-blind, parallel clinical trial

    Journal of Clinical Endocrinology and Metabolism, Vol. 92, Núm. 9, pp. 3446-3452

2006

  1. Efficacy of lanreotide Autogel® administered every 4-8 weeks in patients with acromegaly previously responsive to lanreotide microparticles 30 mg: A phase III trial

    Clinical Endocrinology, Vol. 65, Núm. 3, pp. 320-326

  2. Orlistat reduce la obesidad abdominal. Un metaanálisis

    Revista Espanola de Obesidad, Vol. 4, Núm. 5, pp. 295-300

2004

  1. Epidemiology, clinical characteristics, outcome, morbidity and mortality in acromegaly based on the Spanish Acromegaly Registry (Registro Español de Acromegalia, REA)

    European Journal of Endocrinology, Vol. 151, Núm. 4, pp. 439-446

2003

  1. Preoperative lanreotide treatment for GH-secreting pituitary adenomas: Effect on tumour volume and predictive factors of significant tumour shrinkage

    Clinical Endocrinology, Vol. 58, Núm. 4, pp. 471-481

2002

  1. A single growth hormone (GH) determination is sufficient for the diagnosis of GH-deficiency in adult patients using the growth hormone releasing hormone plus growth hormone releasing peptide-6 test

    Clinical Endocrinology, Vol. 57, Núm. 3, pp. 377-384

  2. Diagnóstico del déficit de hormona del crecimiento en pacientes adultos

    Endocrinologia y Nutricion

  3. Eficacia y seguridad del sildenafilo en varones con diabetes mellitus tipo 2 y disfunción eréctil

    Medicina Clinica, Vol. 119, Núm. 4, pp. 121-124

  4. Ghrelin is no longer able to stimulate growth hormone secretion in patients with Cushing's syndrome but instead induces exaggerated corticotropin and cortisol responses

    Neuroendocrinology, Vol. 76, Núm. 6, pp. 390-396

2000

  1. GH-releasing hormone and GH-releasing peptide-6 for diagnostic testing in GH-deficient adults

    Lancet, Vol. 356, Núm. 9236, pp. 1137-1142